Aptamer: A Targeted Cancer Immuno Therapy

Through distinctive three-dimensional architectures, Targets such as proteins and cells are specifically bound by and interact with single-stranded oligonucleotides. Also known as a "chemical antibody," it exhibits a greater affinity for target molecules than antibodies do, and it offers many therapeutic benefits over antibodies in terms of modification, size, and manufacturing accessibility. They also demonstrated rapid tissue penetration, low immunogenicity, significant biostability, and diverse chemical modification. SELEX stands for Systematic Evolution of Ligands by Exponential Enrichment, which is the process of choosing an aptamer. Recently, reports of novel aptamers have caught the attention of numerous experts. Owing to the ease of chemical alteration and the availability of molecular study, researchers have created freshly designed aptamers conjugated with a variety of therapies, known as aptamer-drug conjugates, or ApDCs, including phototherapy, gene therapy, vaccinations, and chemotherapy. In the therapy of cancer, ApDCs exhibit synergistic therapeutic effects. We enumerate the tumor surface biomarker-targeting aptamers in this review and provide an overview of some representative uses for aptamers. Aptamer-based cancer treatments will find new uses when conjugated with anti-cancer medications and nano vehicles. Aptamer-integrated drug delivery systems therefore have a hitherto untapped potential in bioanalysis and biomedicine. We try to cover the most current developments in cancer therapy targeted medication delivery systems based on aptamers in this brief review. Regarding the choice, alteration, and use of aptamers, significant progress has been accomplished thus far. A small number of aptamer-based products have, nevertheless, already found successful applications in industry and medicine. Here, we also discuss the drawbacks and noteworthy developments in aptamer selection.